Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11334412rdf:typepubmed:Citationlld:pubmed
pubmed-article:11334412lifeskim:mentionsumls-concept:C0752063lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0021655lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0333516lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0071097lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:11334412lifeskim:mentionsumls-concept:C0332291lld:lifeskim
pubmed-article:11334412pubmed:issue5lld:pubmed
pubmed-article:11334412pubmed:dateCreated2001-5-3lld:pubmed
pubmed-article:11334412pubmed:abstractTextTumor necrosis factor (TNF)-alpha is one of the candidate mediators of insulin resistance associated with obesity, a major risk factor for the development of type 2 diabetes. The insulin resistance induced by TNF-alpha is antagonized by thiazolidinediones (TZDs), a new class of insulin-sensitizing drugs. The aim of the current study was to dissect the mechanism whereby pioglitazone, one of the TZDs, ameliorates TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes. Pioglitazone restored insulin-stimulated 2-deoxyglucose (DOG) uptake, which was reduced by TNF-alpha, with concomitant restorations in tyrosine phosphorylation and protein levels of insulin receptor (IR) and insulin receptor substrate (IRS)-1, as well as association of the p85 regulatory subunit of phosphatidylinositol (PI) 3-kinase with IRS-1 and PI 3-kinase activity. Adenovirus-mediated gene transfer of either wild-type human peroxisome proliferator-activated receptor (PPAR)-gamma2 or a mutant carrying a replacement at the consensus mitogen-activated protein kinase phosphorylation site (hPPAR-gamma2-S112A) promoted adipogenesis of 3T3-L1 fibroblasts and restored TNF-alpha-induced decrease of triglyceride in adipocytes as effectively as pioglitazone. Overexpression of the PPAR-gamma proteins in TNF-alpha-treated adipocytes restored protein levels of IR/IRS-1, but did not improve insulin-stimulated tyrosine phosphorylation of IR/IRS-1 or insulin-stimulated 2-DOG uptake. These results indicate that the ability of pioglitazone to restore insulin-stimulated tyrosine phosphorylation of IR/IRS-1, which is necessary for amelioration of TNF-alpha-induced insulin resistance, may be independent of the adipogenic activity of PPAR-gamma that regulates protein levels of IR/IRS-1.lld:pubmed
pubmed-article:11334412pubmed:languageenglld:pubmed
pubmed-article:11334412pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11334412pubmed:statusMEDLINElld:pubmed
pubmed-article:11334412pubmed:monthMaylld:pubmed
pubmed-article:11334412pubmed:issn0012-1797lld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:KobayashiMMlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:UnoTTlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:TakataYYlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:IwataMMlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:SasaokaTTlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:UenoEElld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:HarutaTTlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:KawaharaJJlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:IshibashiOOlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:TakanoAAlld:pubmed
pubmed-article:11334412pubmed:authorpubmed-author:UsuiIIlld:pubmed
pubmed-article:11334412pubmed:issnTypePrintlld:pubmed
pubmed-article:11334412pubmed:volume50lld:pubmed
pubmed-article:11334412pubmed:ownerNLMlld:pubmed
pubmed-article:11334412pubmed:authorsCompleteYlld:pubmed
pubmed-article:11334412pubmed:pagination1083-92lld:pubmed
pubmed-article:11334412pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:meshHeadingpubmed-meshheading:11334412...lld:pubmed
pubmed-article:11334412pubmed:year2001lld:pubmed
pubmed-article:11334412pubmed:articleTitlePioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.lld:pubmed
pubmed-article:11334412pubmed:affiliationFirst Department of Medicine, Toyama Medical and Pharmaceutical University, Japan.lld:pubmed
pubmed-article:11334412pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11334412pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11334412lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11334412lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11334412lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11334412lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11334412lld:pubmed